View ValuationCosmo 将来の成長Future 基準チェック /56Cosmo利益と収益がそれぞれ年間42%と26.7%増加すると予測されています。EPS は年間 増加すると予想されています。自己資本利益率は 3 年後に13.5% 42.1%なると予測されています。主要情報42.0%収益成長率42.06%EPS成長率Pharmaceuticals 収益成長10.1%収益成長率26.7%将来の株主資本利益率13.48%アナリストカバレッジGood最終更新日01 Jun 2026今後の成長に関する最新情報Breakeven Date Change • Dec 31Forecast breakeven date pushed back to 2022The 2 analysts covering Cosmo Pharmaceuticals previously expected the company to break even in 2021. New consensus forecast suggests the company will make a profit of €3.95m in 2022. Average annual earnings growth of 37% is required to achieve expected profit on schedule.Breakeven Date Change • Sep 23Forecast to breakeven in 2021The 3 analysts covering Cosmo Pharmaceuticals expect the company to break even for the first time. New consensus forecast suggests the company will make a profit of €5.22m in 2021. Earnings growth of 59% is required to achieve expected profit on schedule.Breakeven Date Change • Aug 04Forecast breakeven moved forward to 2021The 3 analysts covering Cosmo Pharmaceuticals previously expected the company to break even in 2022. New consensus forecast suggests the company will make a profit of €6.00m in 2021. Earnings growth of 60% is required to achieve expected profit on schedule.すべての更新を表示Recent updatesBoard Change • May 20No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 7 non-independent directors. Executive VP of Corporate Governance, Chief Sustainability Officer & Executive Director Niall Donnelly was the last director to join the board, commencing their role in 2024. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.お知らせ • Mar 14Cosmo Pharmaceuticals N.V., Annual General Meeting, Apr 10, 2026Cosmo Pharmaceuticals N.V., Annual General Meeting, Apr 10, 2026, at 12:00 W. Europe Standard Time.お知らせ • Feb 04Cosmo Pharmaceuticals N.V. announced that it has received funding from Capital Research and Management CompanyCosmo Pharmaceuticals N.V announced that it has completed a private placement with a single institutional investor and issued 937,086 treasury shares representing 5.3% of the company's outstanding shares on February 3, 2026. The transaction included participation from Small cap World Fund of the Capital Group.お知らせ • Jan 09+ 1 more updateCosmo Pharmaceuticals N.V. to Report Fiscal Year 2025 Final Results on Mar 09, 2026Cosmo Pharmaceuticals N.V. announced that they will report fiscal year 2025 final results on Mar 09, 2026お知らせ • Apr 30Cosmo Pharmaceuticals N.V., Annual General Meeting, May 30, 2025Cosmo Pharmaceuticals N.V., Annual General Meeting, May 30, 2025.お知らせ • Apr 01Cosmo Pharmaceuticals N.V. Appoints Federico Sommariva as Chief Legal CounselCosmo Pharmaceuticals N.V. announced the appointment of Federico Sommariva as Chief Legal Counsel. Federico reports to the CEO and is member of the management team. Federico Sommariva has many years of legal and management experience in the Lifesciences industry. Since June 2013, he has worked for Gilead Sciences based in Milan (Italy), with increasing responsibilities. Most recently, he acted as Director and Global Legal Business Partner Oncology. He also served for 1.5 years as interim Head of Legal and Compliance for Gilead Sciences Romania. Federico studied law at the University of Milan and started his professional career as Legal Counsel Secondee at H&M in Rome (Italy).お知らせ • Feb 11Cosmo Pharmaceuticals N.V. Announces the Appointment of Andrea Cherubini as Chief AI OfficerCosmo Pharmaceuticals N.V. announced the appointment of Andrea Cherubini as Chief AI Officer effective immediately. This important decision reflects Cosmo's commitment to integrating Artificial Intelligence as a core strategic pillar in its future growth and innovation roadmap. Andrea will report to the CEO and will be member of the executive leadership team. Andrea has been pivotal in the development and commercialization of Cosmo's GI GeniusT. As Senior Vice President - Science, AI, and Data, he was leading the development of innovative AI solutions for the Cosmo Intelligent Medical Devices division since 2018. His extensive clinical expertise, data-driven approach, and leadership in AI have already transformed patient outcomes, showcasing the real-world impact of AI in medical applications. AI as a Strategic Growth Driver In his new role as Chief AI Officer, Andrea will spearhead the expansion of AI beyond endoscopy, embedding it across Cosmo's entire portfolio to accelerate innovation, enhance efficiencies, and unlock new value for both patients and shareholders. This includes, among others: Gastroenterology Pipeline - Advancing AI applications in drug development, particularly for Bile Acid Diarrhea (BAD), to drive precision medicine and predictive analytics in GI disorders. Dermatology Pipeline - Leveraging AI to optimize clinical trial design, patient selection, and personalized treatment pathways for Breezula and other dermatological innovations. AI-Enabled Drug Discovery & Development - Expanding AI's role in R&D, regulatory strategies, and digital health applications, reinforcing Cosmo's position as a leader in AI-driven healthcare solutions. At the same time, Andrea will continue to play a critical role in shaping Cosmo's Intelligent Medical Devices division's AI roadmap, reinforcing GI GeniusT as the leading real-time AI platform in endoscopy.お知らせ • Jan 21+ 1 more updateCosmo Pharmaceuticals N.V. to Report Fiscal Year 2024 Results on Mar 06, 2025Cosmo Pharmaceuticals N.V. announced that they will report fiscal year 2024 results on Mar 06, 2025お知らせ • Jan 08Cosmo Pharmaceuticals N.V. to Report Fiscal Year 2024 Final Results on Mar 20, 2025Cosmo Pharmaceuticals N.V. announced that they will report fiscal year 2024 final results at 12:00 PM, Central European Standard Time on Mar 20, 2025お知らせ • Oct 12Cosmo Pharmaceuticals N.V. Announces Chief Financial Officer ChangesCosmo Pharmaceuticals N.V. announced the appointment of Svetlana Sigalova as its new Chief Financial Officer, effective November 11, 2024. Svetlana will succeed Niall Donnelly, who has served as CFO since 2016. Svetlana Sigalova brings a wealth of expertise from her time at Moderna, where she served as Vice President of Commercial Finance and led the financial operations for over $6 billion in global sales. Her proven ability to develop financial infrastructure and planning systems was pivotal in Moderna's rapid growth during the pandemic. Prior to Moderna, Svetlana held senior finance leadership positions at Alexion Pharmaceuticals and Vertex Pharmaceuticals, where she managed multibillion-dollar revenue streams, built high-performance finance teams, and drove operational efficiency. Niall will transition to a strategic new role as EVP - Corporate Governance & Chief Sustainability Officer, where he will report to CEO and play a key part in strengthening Cosmo's corporate governance framework and driving the Company's mission to advance environmental, social, and governance (ESG) initiatives. With a focus on achieving carbon footprint reduction and sustainable business practices, Niall's leadership will ensure Cosmo continues to build a strong and responsible organization with a robust governance structure that aligns with the Company's long-term growth and value creation. He will also remain an executive member of the Board of Directors of Cosmo.お知らせ • Apr 28Cosmo Pharmaceuticals N.V. Announces Executive Changes at the Upcoming Annual General Meeting on 24 May 2024Cosmo Pharmaceuticals N.V. announced the appointment of Giovanni Di Napoli as its new Chief Executive Officer, along with changes to its Board of Directors, at the upcoming Annual General Meeting (AGM) on 24 May 2024. At the same time, it will be proposed at the AGM to appoint longstanding Cosmo CEO Alessandro Della Cha as the new Chairman of Cosmo. Alessandro joined Cosmo in 2006 as member of the Board of Directors and was appointed as CEO of the Company in 2014. Giovanni is an accomplished leader with an excellent track record and joins Cosmo from Medtronic where he held various leadership positions since 2008. Until recently, Giovanni was President of Medtronic's Endoscopy Operating Unit located in Santa Clara, California. In this position, he and his team were responsible for one of the most innovative and fast-growing portfolios in the endoscopy market, which included technologies such as Endoflip, Pillcam, and GI Genius. From July 2017 to November 2020, he was Vice President and General Manager GIH - Gastrointestinal and Hepatology and was Vice President Sales U.S. - GI Solutions from February 2015 to July 2017. From April 2012 to February 2015, he was Director of Sales Marketing for Western Europe. Previously, Giovanni held various leadership positions at Johnson Johnson Medical (2001- 2010). Giovanni has an MBA from the Universita Bocconi, Milan, Italy.New Risk • Mar 24New major risk - Dividend sustainabilityThe dividend is not well covered by earnings and cash flows. Dividend per share is over 28x earnings per share. Cash payout ratio: 175% Dividend yield: 2.9% This is considered a major risk. Companies that pay out too much of their earnings and cash flows are at risk of having to reduce or cut their dividend in future. If earnings or cash flows stagnate or fall, then there may not be enough to maintain the same dividend. Or in extreme cases, companies may opt to dig into capital reserves or take on debt to maintain the dividend. For dividend paying companies, any reduction in the dividend can significantly impact the share price. Currently, the following risks have been identified for the company: Major Risk Dividend is not well covered by earnings and cash flows. Dividend per share is over 28x earnings per share. Cash payout ratio: 175% Minor Risks Large one-off items impacting financial results. Profit margins are more than 30% lower than last year (1.2% net profit margin).Reported Earnings • Mar 22Full year 2023 earnings released: EPS: €0.071 (vs €1.05 in FY 2022)Full year 2023 results: EPS: €0.071 (down from €1.05 in FY 2022). Revenue: €96.7m (down 5.3% from FY 2022). Net income: €1.15m (down 93% from FY 2022). Profit margin: 1.2% (down from 17% in FY 2022). The decrease in margin was primarily driven by higher expenses. Revenue is forecast to grow 26% p.a. on average during the next 3 years, compared to a 5.8% growth forecast for the Pharmaceuticals industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 37% per year but the company’s share price has fallen by 8% per year, which means it is significantly lagging earnings.お知らせ • Mar 22Cosmo Pharmaceuticals N.V. to Report Fiscal Year 2023 Final Results on Apr 30, 2024Cosmo Pharmaceuticals N.V. announced that they will report fiscal year 2023 final results on Apr 30, 2024お知らせ • Feb 15Cosmo Pharmaceuticals N.V. to Report First Half, 2024 Results on Jul 25, 2024Cosmo Pharmaceuticals N.V. announced that they will report first half, 2024 results on Jul 25, 2024お知らせ • Dec 06+ 1 more updateCosmo Pharmaceuticals N.V., Annual General Meeting, May 24, 2024Cosmo Pharmaceuticals N.V., Annual General Meeting, May 24, 2024.Reported Earnings • Jul 28First half 2023 earnings released: EPS: €0.092 (vs €0.48 in 1H 2022)First half 2023 results: EPS: €0.092 (down from €0.48 in 1H 2022). Revenue: €43.7m (up 5.2% from 1H 2022). Net income: €1.49m (down 81% from 1H 2022). Profit margin: 3.4% (down from 19% in 1H 2022). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 28% p.a. on average during the next 3 years, compared to a 6.5% growth forecast for the Pharmaceuticals industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 78% per year but the company’s share price has fallen by 21% per year, which means it is significantly lagging earnings.Upcoming Dividend • May 24Upcoming dividend of €1.05 per share at 2.0% yieldEligible shareholders must have bought the stock before 31 May 2023. Payment date: 02 June 2023. The company is paying out more than 100% of its profits but is generating plenty of cash to support the dividend. Trailing yield: 2.0%. Lower than top quartile of British dividend payers (5.8%). Lower than average of industry peers (2.4%).Reported Earnings • Mar 25Full year 2022 earnings released: EPS: €1.05 (vs €1.29 in FY 2021)Full year 2022 results: EPS: €1.05 (down from €1.29 in FY 2021). Revenue: €102.1m (up 57% from FY 2021). Net income: €17.2m (down 21% from FY 2021). Profit margin: 17% (down from 33% in FY 2021). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 24% p.a. on average during the next 3 years, compared to a 6.5% growth forecast for the Pharmaceuticals industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 106% per year but the company’s share price has fallen by 4% per year, which means it is significantly lagging earnings.お知らせ • Dec 20+ 2 more updatesCosmo Pharmaceuticals N.V., Annual General Meeting, May 26, 2023Cosmo Pharmaceuticals N.V., Annual General Meeting, May 26, 2023.Board Change • Nov 16No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 8 experienced directors. 4 highly experienced directors. No independent directors (7 non-independent directors). Non-Executive Director Kevin Donovan was the last director to join the board, commencing their role in 2016. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.Reported Earnings • Jul 29First half 2022 earnings releasedFirst half 2022 results: Revenue: (down 100% from 1H 2021). Net income: (up €5.74m from 1H 2021). Profit margin: (up from net loss in 1H 2021). The move to profitability was driven by lower expenses. Over the next year, revenue is forecast to grow 50% while the industry in the United Kingdom is not expected to grow. Over the last 3 years on average, earnings per share has increased by 110% per year but the company’s share price has fallen by 15% per year, which means it is significantly lagging earnings.Valuation Update With 7 Day Price Move • Jun 17Investor sentiment deteriorated over the past weekAfter last week's 15% share price decline to CHF42.90, the stock trades at a forward P/E ratio of 41x. Average forward P/E is 19x in the Pharmaceuticals industry in the United Kingdom. Total loss to shareholders of 52% over the past three years.Board Change • Apr 27No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 8 experienced directors. 4 highly experienced directors. No independent directors (7 non-independent directors). Non-Executive Director Kevin Donovan was the last director to join the board, commencing their role in 2016. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.Breakeven Date Change • Dec 31Forecast breakeven date pushed back to 2022The 2 analysts covering Cosmo Pharmaceuticals previously expected the company to break even in 2021. New consensus forecast suggests the company will make a profit of €3.95m in 2022. Average annual earnings growth of 37% is required to achieve expected profit on schedule.Executive Departure • Nov 29Non-Executive Director Eimear Cowhey has left the companyOn the 16th of November, Eimear Cowhey's tenure as Non-Executive Director ended after 4.5 years in the role. We don't have any record of a personal shareholding under Eimear's name. A total of 3 executives have left over the last 12 months. The current median tenure of the management team is 5.25 years.Executive Departure • Nov 29Non-Executive Director Eimear Cowhey has left the companyOn the 16th of November, Eimear Cowhey's tenure as Non-Executive Director ended after 4.5 years in the role. We don't have any record of a personal shareholding under Eimear's name. A total of 3 executives have left over the last 12 months. The current median tenure of the management team is 5.25 years.Executive Departure • Nov 29Non-Executive Director Eimear Cowhey has left the companyOn the 16th of November, Eimear Cowhey's tenure as Non-Executive Director ended after 4.5 years in the role. We don't have any record of a personal shareholding under Eimear's name. A total of 3 executives have left over the last 12 months. The current median tenure of the management team is 5.25 years.Executive Departure • Nov 29Non-Executive Director Eimear Cowhey has left the companyOn the 16th of November, Eimear Cowhey's tenure as Non-Executive Director ended after 4.5 years in the role. We don't have any record of a personal shareholding under Eimear's name. A total of 3 executives have left over the last 12 months. The current median tenure of the management team is 5.25 years.Executive Departure • Nov 29Non-Executive Director Eimear Cowhey has left the companyOn the 16th of November, Eimear Cowhey's tenure as Non-Executive Director ended after 4.5 years in the role. We don't have any record of a personal shareholding under Eimear's name. A total of 3 executives have left over the last 12 months. The current median tenure of the management team is 5.25 years.Executive Departure • Nov 29Non-Executive Director Eimear Cowhey has left the companyOn the 16th of November, Eimear Cowhey's tenure as Non-Executive Director ended after 4.5 years in the role. We don't have any record of a personal shareholding under Eimear's name. A total of 3 executives have left over the last 12 months. The current median tenure of the management team is 5.25 years.Executive Departure • Nov 29Non-Executive Director Eimear Cowhey has left the companyOn the 16th of November, Eimear Cowhey's tenure as Non-Executive Director ended after 4.5 years in the role. We don't have any record of a personal shareholding under Eimear's name. A total of 3 executives have left over the last 12 months. The current median tenure of the management team is 5.25 years.Executive Departure • Nov 28Non-Executive Director Eimear Cowhey has left the companyOn the 16th of November, Eimear Cowhey's tenure as Non-Executive Director ended after 4.5 years in the role. We don't have any record of a personal shareholding under Eimear's name. A total of 3 executives have left over the last 12 months. The current median tenure of the management team is 5.25 years.Executive Departure • Nov 28Non-Executive Director Eimear Cowhey has left the companyOn the 16th of November, Eimear Cowhey's tenure as Non-Executive Director ended after 4.5 years in the role. We don't have any record of a personal shareholding under Eimear's name. A total of 3 executives have left over the last 12 months. The current median tenure of the management team is 5.25 years.Executive Departure • Nov 28Non-Executive Director Eimear Cowhey has left the companyOn the 16th of November, Eimear Cowhey's tenure as Non-Executive Director ended after 4.5 years in the role. We don't have any record of a personal shareholding under Eimear's name. A total of 3 executives have left over the last 12 months. The current median tenure of the management team is 5.25 years.Executive Departure • Nov 28Non-Executive Director Eimear Cowhey has left the companyOn the 16th of November, Eimear Cowhey's tenure as Non-Executive Director ended after 4.5 years in the role. We don't have any record of a personal shareholding under Eimear's name. A total of 3 executives have left over the last 12 months. The current median tenure of the management team is 5.25 years.Executive Departure • Nov 28Non-Executive Director Eimear Cowhey has left the companyOn the 16th of November, Eimear Cowhey's tenure as Non-Executive Director ended after 4.5 years in the role. We don't have any record of a personal shareholding under Eimear's name. A total of 3 executives have left over the last 12 months. The current median tenure of the management team is 5.25 years.Executive Departure • Nov 28Non-Executive Director Eimear Cowhey has left the companyOn the 16th of November, Eimear Cowhey's tenure as Non-Executive Director ended after 4.5 years in the role. We don't have any record of a personal shareholding under Eimear's name. A total of 3 executives have left over the last 12 months. The current median tenure of the management team is 5.25 years.Executive Departure • Nov 28Non-Executive Director Eimear Cowhey has left the companyOn the 16th of November, Eimear Cowhey's tenure as Non-Executive Director ended after 4.5 years in the role. We don't have any record of a personal shareholding under Eimear's name. A total of 3 executives have left over the last 12 months. The current median tenure of the management team is 5.25 years.Executive Departure • Nov 28Non-Executive Director Eimear Cowhey has left the companyOn the 16th of November, Eimear Cowhey's tenure as Non-Executive Director ended after 4.5 years in the role. We don't have any record of a personal shareholding under Eimear's name. A total of 3 executives have left over the last 12 months. The current median tenure of the management team is 5.25 years.Executive Departure • Nov 27Non-Executive Director Eimear Cowhey has left the companyOn the 16th of November, Eimear Cowhey's tenure as Non-Executive Director ended after 4.5 years in the role. We don't have any record of a personal shareholding under Eimear's name. A total of 3 executives have left over the last 12 months. The current median tenure of the management team is 5.25 years.Executive Departure • Nov 27Non-Executive Director Eimear Cowhey has left the companyOn the 16th of November, Eimear Cowhey's tenure as Non-Executive Director ended after 4.5 years in the role. We don't have any record of a personal shareholding under Eimear's name. A total of 3 executives have left over the last 12 months. The current median tenure of the management team is 5.25 years.Executive Departure • Nov 27Non-Executive Director Eimear Cowhey has left the companyOn the 16th of November, Eimear Cowhey's tenure as Non-Executive Director ended after 4.5 years in the role. We don't have any record of a personal shareholding under Eimear's name. A total of 3 executives have left over the last 12 months. The current median tenure of the management team is 5.25 years.Executive Departure • Nov 27Non-Executive Director Eimear Cowhey has left the companyOn the 16th of November, Eimear Cowhey's tenure as Non-Executive Director ended after 4.5 years in the role. We don't have any record of a personal shareholding under Eimear's name. A total of 3 executives have left over the last 12 months. The current median tenure of the management team is 5.25 years.Executive Departure • Nov 27Non-Executive Director Eimear Cowhey has left the companyOn the 16th of November, Eimear Cowhey's tenure as Non-Executive Director ended after 4.5 years in the role. We don't have any record of a personal shareholding under Eimear's name. A total of 3 executives have left over the last 12 months. The current median tenure of the management team is 5.25 years.Executive Departure • Nov 27Non-Executive Director Eimear Cowhey has left the companyOn the 16th of November, Eimear Cowhey's tenure as Non-Executive Director ended after 4.5 years in the role. We don't have any record of a personal shareholding under Eimear's name. A total of 3 executives have left over the last 12 months. The current median tenure of the management team is 5.25 years.Executive Departure • Nov 27Non-Executive Director Eimear Cowhey has left the companyOn the 16th of November, Eimear Cowhey's tenure as Non-Executive Director ended after 4.5 years in the role. We don't have any record of a personal shareholding under Eimear's name. A total of 3 executives have left over the last 12 months. The current median tenure of the management team is 5.25 years.Executive Departure • Nov 27Non-Executive Director Eimear Cowhey has left the companyOn the 16th of November, Eimear Cowhey's tenure as Non-Executive Director ended after 4.5 years in the role. We don't have any record of a personal shareholding under Eimear's name. A total of 3 executives have left over the last 12 months. The current median tenure of the management team is 5.25 years.Executive Departure • Nov 27Non-Executive Director Eimear Cowhey has left the companyOn the 16th of November, Eimear Cowhey's tenure as Non-Executive Director ended after 4.5 years in the role. We don't have any record of a personal shareholding under Eimear's name. A total of 3 executives have left over the last 12 months. The current median tenure of the management team is 5.25 years.Executive Departure • Nov 27Non-Executive Director Eimear Cowhey has left the companyOn the 16th of November, Eimear Cowhey's tenure as Non-Executive Director ended after 4.5 years in the role. We don't have any record of a personal shareholding under Eimear's name. A total of 3 executives have left over the last 12 months. The current median tenure of the management team is 5.25 years.Executive Departure • Nov 27Non-Executive Director Eimear Cowhey has left the companyOn the 16th of November, Eimear Cowhey's tenure as Non-Executive Director ended after 4.5 years in the role. We don't have any record of a personal shareholding under Eimear's name. A total of 3 executives have left over the last 12 months. The current median tenure of the management team is 5.25 years.Executive Departure • Nov 27Non-Executive Director Eimear Cowhey has left the companyOn the 16th of November, Eimear Cowhey's tenure as Non-Executive Director ended after 4.5 years in the role. We don't have any record of a personal shareholding under Eimear's name. A total of 3 executives have left over the last 12 months. The current median tenure of the management team is 5.25 years.Executive Departure • Nov 27Non-Executive Director Eimear Cowhey has left the companyOn the 16th of November, Eimear Cowhey's tenure as Non-Executive Director ended after 4.5 years in the role. We don't have any record of a personal shareholding under Eimear's name. A total of 3 executives have left over the last 12 months. The current median tenure of the management team is 5.25 years.Executive Departure • Nov 27Non-Executive Director Eimear Cowhey has left the companyOn the 16th of November, Eimear Cowhey's tenure as Non-Executive Director ended after 4.5 years in the role. We don't have any record of a personal shareholding under Eimear's name. A total of 3 executives have left over the last 12 months. The current median tenure of the management team is 5.25 years.Executive Departure • Nov 27Non-Executive Director Eimear Cowhey has left the companyOn the 16th of November, Eimear Cowhey's tenure as Non-Executive Director ended after 4.5 years in the role. We don't have any record of a personal shareholding under Eimear's name. A total of 3 executives have left over the last 12 months. The current median tenure of the management team is 5.25 years.Executive Departure • Nov 27Non-Executive Director Eimear Cowhey has left the companyOn the 16th of November, Eimear Cowhey's tenure as Non-Executive Director ended after 4.5 years in the role. We don't have any record of a personal shareholding under Eimear's name. A total of 3 executives have left over the last 12 months. The current median tenure of the management team is 5.25 years.Executive Departure • Nov 26Non-Executive Director Eimear Cowhey has left the companyOn the 16th of November, Eimear Cowhey's tenure as Non-Executive Director ended after 4.5 years in the role. We don't have any record of a personal shareholding under Eimear's name. A total of 3 executives have left over the last 12 months. The current median tenure of the management team is 5.25 years.Executive Departure • Nov 26Non-Executive Director Eimear Cowhey has left the companyOn the 16th of November, Eimear Cowhey's tenure as Non-Executive Director ended after 4.5 years in the role. We don't have any record of a personal shareholding under Eimear's name. A total of 3 executives have left over the last 12 months. The current median tenure of the management team is 5.25 years.Executive Departure • Nov 26Non-Executive Director Eimear Cowhey has left the companyOn the 16th of November, Eimear Cowhey's tenure as Non-Executive Director ended after 4.5 years in the role. We don't have any record of a personal shareholding under Eimear's name. A total of 3 executives have left over the last 12 months. The current median tenure of the management team is 5.25 years.Executive Departure • Nov 26Non-Executive Director Eimear Cowhey has left the companyOn the 16th of November, Eimear Cowhey's tenure as Non-Executive Director ended after 4.5 years in the role. We don't have any record of a personal shareholding under Eimear's name. A total of 3 executives have left over the last 12 months. The current median tenure of the management team is 5.25 years.Executive Departure • Nov 26Non-Executive Director Eimear Cowhey has left the companyOn the 16th of November, Eimear Cowhey's tenure as Non-Executive Director ended after 4.5 years in the role. We don't have any record of a personal shareholding under Eimear's name. A total of 3 executives have left over the last 12 months. The current median tenure of the management team is 5.25 years.Executive Departure • Nov 26Non-Executive Director Eimear Cowhey has left the companyOn the 16th of November, Eimear Cowhey's tenure as Non-Executive Director ended after 4.5 years in the role. We don't have any record of a personal shareholding under Eimear's name. A total of 3 executives have left over the last 12 months. The current median tenure of the management team is 5.25 years.Executive Departure • Nov 26Non-Executive Director Eimear Cowhey has left the companyOn the 16th of November, Eimear Cowhey's tenure as Non-Executive Director ended after 4.5 years in the role. We don't have any record of a personal shareholding under Eimear's name. A total of 3 executives have left over the last 12 months. The current median tenure of the management team is 5.25 years.Executive Departure • Nov 26Non-Executive Director Eimear Cowhey has left the companyOn the 16th of November, Eimear Cowhey's tenure as Non-Executive Director ended after 4.5 years in the role. We don't have any record of a personal shareholding under Eimear's name. A total of 3 executives have left over the last 12 months. The current median tenure of the management team is 5.25 years.Executive Departure • Nov 26Non-Executive Director Eimear Cowhey has left the companyOn the 16th of November, Eimear Cowhey's tenure as Non-Executive Director ended after 4.5 years in the role. We don't have any record of a personal shareholding under Eimear's name. A total of 3 executives have left over the last 12 months. The current median tenure of the management team is 5.25 years.Executive Departure • Nov 26Non-Executive Director Eimear Cowhey has left the companyOn the 16th of November, Eimear Cowhey's tenure as Non-Executive Director ended after 4.5 years in the role. We don't have any record of a personal shareholding under Eimear's name. A total of 3 executives have left over the last 12 months. The current median tenure of the management team is 5.25 years.Executive Departure • Nov 26Non-Executive Director Eimear Cowhey has left the companyOn the 16th of November, Eimear Cowhey's tenure as Non-Executive Director ended after 4.5 years in the role. We don't have any record of a personal shareholding under Eimear's name. A total of 3 executives have left over the last 12 months. The current median tenure of the management team is 5.25 years.Executive Departure • Nov 26Non-Executive Director Eimear Cowhey has left the companyOn the 16th of November, Eimear Cowhey's tenure as Non-Executive Director ended after 4.5 years in the role. We don't have any record of a personal shareholding under Eimear's name. A total of 3 executives have left over the last 12 months. The current median tenure of the management team is 5.25 years.Executive Departure • Nov 25Non-Executive Director Eimear Cowhey has left the companyOn the 16th of November, Eimear Cowhey's tenure as Non-Executive Director ended after 4.5 years in the role. We don't have any record of a personal shareholding under Eimear's name. A total of 3 executives have left over the last 12 months. The current median tenure of the management team is 5.25 years.Executive Departure • Nov 25Non-Executive Director Eimear Cowhey has left the companyOn the 16th of November, Eimear Cowhey's tenure as Non-Executive Director ended after 4.5 years in the role. We don't have any record of a personal shareholding under Eimear's name. A total of 3 executives have left over the last 12 months. The current median tenure of the management team is 5.25 years.Executive Departure • Nov 25Non-Executive Director Eimear Cowhey has left the companyOn the 16th of November, Eimear Cowhey's tenure as Non-Executive Director ended after 4.5 years in the role. We don't have any record of a personal shareholding under Eimear's name. A total of 3 executives have left over the last 12 months. The current median tenure of the management team is 5.25 years.Executive Departure • Nov 25Non-Executive Director Eimear Cowhey has left the companyOn the 16th of November, Eimear Cowhey's tenure as Non-Executive Director ended after 4.5 years in the role. We don't have any record of a personal shareholding under Eimear's name. A total of 3 executives have left over the last 12 months. The current median tenure of the management team is 5.25 years.Executive Departure • Nov 25Non-Executive Director Eimear Cowhey has left the companyOn the 16th of November, Eimear Cowhey's tenure as Non-Executive Director ended after 4.5 years in the role. We don't have any record of a personal shareholding under Eimear's name. A total of 3 executives have left over the last 12 months. The current median tenure of the management team is 5.25 years.Executive Departure • Nov 25Non-Executive Director Eimear Cowhey has left the companyOn the 16th of November, Eimear Cowhey's tenure as Non-Executive Director ended after 4.5 years in the role. We don't have any record of a personal shareholding under Eimear's name. A total of 3 executives have left over the last 12 months. The current median tenure of the management team is 5.25 years.Executive Departure • Nov 25Non-Executive Director Eimear Cowhey has left the companyOn the 16th of November, Eimear Cowhey's tenure as Non-Executive Director ended after 4.5 years in the role. We don't have any record of a personal shareholding under Eimear's name. A total of 3 executives have left over the last 12 months. The current median tenure of the management team is 5.25 years.Executive Departure • Nov 25Non-Executive Director Eimear Cowhey has left the companyOn the 16th of November, Eimear Cowhey's tenure as Non-Executive Director ended after 4.5 years in the role. We don't have any record of a personal shareholding under Eimear's name. A total of 3 executives have left over the last 12 months. The current median tenure of the management team is 5.25 years.Breakeven Date Change • Sep 23Forecast to breakeven in 2021The 3 analysts covering Cosmo Pharmaceuticals expect the company to break even for the first time. New consensus forecast suggests the company will make a profit of €5.22m in 2021. Earnings growth of 59% is required to achieve expected profit on schedule.Breakeven Date Change • Aug 04Forecast breakeven moved forward to 2021The 3 analysts covering Cosmo Pharmaceuticals previously expected the company to break even in 2022. New consensus forecast suggests the company will make a profit of €6.00m in 2021. Earnings growth of 60% is required to achieve expected profit on schedule.Reported Earnings • Aug 02First half 2021 earnings released: €0.40 loss per share (vs €0.21 loss in 1H 2020)The company reported a soft first half result with increased losses and weaker control over costs, although revenues improved. First half 2021 results: Revenue: €28.4m (up 9.8% from 1H 2020). Net loss: €5.74m (loss widened 90% from 1H 2020). Over the last 3 years on average, earnings per share has increased by 34% per year but the company’s share price has fallen by 14% per year, which means it is significantly lagging earnings.Executive Departure • Jun 04Non-Executive Director Hans Tanner has left the companyOn the 29th of May, Hans Tanner's tenure as Non-Executive Director ended. We don't have any record of a personal shareholding under Hans' name. A total of 3 executives have left over the last 12 months. The current median tenure of the management team is 4.83 years.Reported Earnings • Mar 27Full year 2020 earnings released: €0.55 loss per share (vs €1.67 loss in FY 2019)The company reported a decent full year result with reduced losses and improved control over expenses, although revenues were weaker. Full year 2020 results: Revenue: €60.9m (down 2.5% from FY 2019). Net loss: €7.90m (loss narrowed 68% from FY 2019). Over the last 3 years on average, earnings per share has increased by 33% per year but the company’s share price has fallen by 13% per year, which means it is significantly lagging earnings.Is New 90 Day High Low • Feb 06New 90-day high: CHF87.80The company is up 10.0% from its price of CHF79.90 on 06 November 2020. The British market is up 12% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Pharmaceuticals industry, which is down 11% over the same period.お知らせ • Dec 04Cosmo Pharmaceuticals Announces Licence of Lumeblue (Methylene Blue MMX) China Rights to China Medical System Holdings LtdCosmo Pharmaceuticals N.V. announced that it has licensed the Chinese rights for Lumeblue™ to China Medical System Holdings Ltd. Lumeblue™ is Cosmo's recently EMA approved drug for the detection of lesions during colonoscopy. CMS is a well-established, innovation-driven specialty pharma with a focus on sales and marketing in China. CMS concentrates on innovative products that are global first-in-class or with the best efficacy or best cost-effectiveness in the same class due to their innovative formulations or drug delivery systems, and has built up an innovative pipeline with great market potential and competitive differentiation advantages at relatively high innovation level, covering various therapeutic fields. Meanwhile, CMS has proven and successful experience in drug promotion for over two decades, and established a professional, compliant and efficient academic promotion system. CMS is listed on the Main Board of the Stock Exchange of Hong Kong. CMS will pay Cosmo a USD 5m upon the earlier of (a) the execution of a supply agreement or (b) the forty-fifth (45th) day from the execution of this agreement, plus royalties and potential regulatory and commercial milestones. Cosmo will be the exclusive supplier of Lumeblue™.お知らせ • Dec 01Cosmo Pharmaceuticals Appoints H. Jurgen Lenz as New Chief Medical OfficerCosmo Pharmaceuticals N.V. announced that Dr. H. Jurgen Lenz, MD, has been appointed Chief Medical Officer starting from December 1st, 2020. Dr. Lenz is a gastroenterologist and is Chief of the Division of Gastroenterology at Scripps Memorial Hospital, La Jolla, CA, USA. He is member of the American Gastroenterological Association (AGA), American College of Gastroenterology (ACG), American Society for Gastrointestinal Endoscopy (ASGE) and American Association for the Study of Liver Diseases (AASLD).お知らせ • Nov 24Cosmo Pharmaceuticals N.V. Announces Senior Leadership Changes, Effective January 1, 2021Cosmo Pharmaceuticals N.V. announced two senior leadership changes which will take effect from the 1st of January 2021. Mr. Giuseppe Cipriano, the current COO, will be appointed to the position of Chief People Officer of Cosmo and will take the lead for all aspects related to managing human resources and industrial relations. Mr. Cipriano has been COO since 2001. Mr. Marco Lecchi, the current Head of Internal Audit, will be appointed to the position of Chief Operating Officer. Mr. Lecchi has been with Cosmo since 2001 and served as Deputy CFO since 2007 prior to his appointment as Head of Internal Audit in 2016.お知らせ • Nov 19Cosmo Pharmaceuticals Announces Expansion of Agreement with Dr. Falk Pharma for Rifamycin SV MMXCosmo Pharmaceuticals N.V. announced that it has expanded its existing license agreement with Dr. Falk Pharma Gmbh ("Dr. Falk") to include Rifamycin SV MMX in the new 600mg formulation currently tested in the IBS-D indication. Under the agreement with Dr Falk, Cosmo will receive a further &euro2m down-payment plus reimbursement of a portion of the expenses borne for the development of the 600mg formulation plus a supply price which incorporates a high double-digit percentage of sales. Dr. Falk will also bear a portion of the future costs for the ongoing developments. Rifamycin SV MMX 200mg is already approved in the US and EU for the treatment of travelers' diarrhea and it is licensed to Dr. Falk for the EU and other countries and is marketed under the brand name Relafalk®, whereas it is licensed to RedHill BioPharma Ltd. for the US where it is marketed under the brand name Aemcolo®. A Phase II clinical study with Rifamycin 600mg in IBS-D indication is currently ongoing and results are expected by year end.業績と収益の成長予測BATS-CHIXE:COPNZ - アナリストの将来予測と過去の財務データ ( )EUR Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数12/31/2028217589784512/31/2027179508470512/31/202610711216612/31/2025104-4-18-12N/A9/30/2025143282431N/A6/30/2025182606774N/A3/31/202522597112118N/A12/31/2024267133157162N/A9/30/202422696127130N/A6/30/2024185599897N/A3/31/2024139245860N/A12/31/202393-111823N/A9/30/20239902129N/A6/30/2023104112436N/A3/31/2023103142535N/A12/31/2022102172633N/A9/30/202290261724N/A6/30/20227835816N/A3/31/20227228614N/A12/31/20216522413N/A9/30/2021646816N/A6/30/202163-111219N/A3/31/202162-9816N/A12/31/202061-8513N/A9/30/202064-7-16N/A6/30/202067-7-80N/A3/31/202065-16-22-9N/A12/31/201962-24-36-19N/A9/30/201956-28N/A-17N/A6/30/201950-31N/A-15N/A3/31/201958-24N/A-12N/A12/31/201866-18N/A-10N/A9/30/201869-20N/A-10N/A6/30/201873-23N/A-11N/A3/31/201870-28N/A-10N/A12/31/201768-32N/A-9N/A9/30/201768-18N/A-6N/A6/30/201769-4N/A-2N/A3/31/2017698N/A10N/A12/31/20166819N/A22N/A9/30/20167018N/A18N/A6/30/20167216N/A14N/A3/31/201666132N/A-13N/A12/31/201561248N/A-39N/A9/30/201560241N/A-13N/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: COPNZは今後 3 年間で収益性が向上すると予測されており、これは 貯蓄率 ( 3.4% ) よりも高い成長率であると考えられます。収益対市場: COPNZ今後 3 年間で収益性が向上すると予想されており、これは市場平均を上回る成長と考えられます。高成長収益: COPNZ今後 3 年以内に収益を上げることが予想されます。収益対市場: COPNZの収益 ( 26.7% ) UK市場 ( 4.7% ) よりも速いペースで成長すると予測されています。高い収益成長: COPNZの収益 ( 26.7% ) 20%よりも速いペースで成長すると予測されています。一株当たり利益成長率予想将来の株主資本利益率将来のROE: COPNZの 自己資本利益率 は、3年後には低くなると予測されています ( 13.5 %)。成長企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/07/07 19:10終値2026/07/07 00:00収益2025/12/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社の Github ページ でご覧いただけます。また、レポートの使い方に関する ガイド や YouTube の チュートリアル もご用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Cosmo N.V. 6 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。11 アナリスト機関Estelle BétriseyBerenbergLaura HindleyBerenbergKerry HolfordBerenberg8 その他のアナリストを表示
Breakeven Date Change • Dec 31Forecast breakeven date pushed back to 2022The 2 analysts covering Cosmo Pharmaceuticals previously expected the company to break even in 2021. New consensus forecast suggests the company will make a profit of €3.95m in 2022. Average annual earnings growth of 37% is required to achieve expected profit on schedule.
Breakeven Date Change • Sep 23Forecast to breakeven in 2021The 3 analysts covering Cosmo Pharmaceuticals expect the company to break even for the first time. New consensus forecast suggests the company will make a profit of €5.22m in 2021. Earnings growth of 59% is required to achieve expected profit on schedule.
Breakeven Date Change • Aug 04Forecast breakeven moved forward to 2021The 3 analysts covering Cosmo Pharmaceuticals previously expected the company to break even in 2022. New consensus forecast suggests the company will make a profit of €6.00m in 2021. Earnings growth of 60% is required to achieve expected profit on schedule.
Board Change • May 20No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 7 non-independent directors. Executive VP of Corporate Governance, Chief Sustainability Officer & Executive Director Niall Donnelly was the last director to join the board, commencing their role in 2024. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.
お知らせ • Mar 14Cosmo Pharmaceuticals N.V., Annual General Meeting, Apr 10, 2026Cosmo Pharmaceuticals N.V., Annual General Meeting, Apr 10, 2026, at 12:00 W. Europe Standard Time.
お知らせ • Feb 04Cosmo Pharmaceuticals N.V. announced that it has received funding from Capital Research and Management CompanyCosmo Pharmaceuticals N.V announced that it has completed a private placement with a single institutional investor and issued 937,086 treasury shares representing 5.3% of the company's outstanding shares on February 3, 2026. The transaction included participation from Small cap World Fund of the Capital Group.
お知らせ • Jan 09+ 1 more updateCosmo Pharmaceuticals N.V. to Report Fiscal Year 2025 Final Results on Mar 09, 2026Cosmo Pharmaceuticals N.V. announced that they will report fiscal year 2025 final results on Mar 09, 2026
お知らせ • Apr 30Cosmo Pharmaceuticals N.V., Annual General Meeting, May 30, 2025Cosmo Pharmaceuticals N.V., Annual General Meeting, May 30, 2025.
お知らせ • Apr 01Cosmo Pharmaceuticals N.V. Appoints Federico Sommariva as Chief Legal CounselCosmo Pharmaceuticals N.V. announced the appointment of Federico Sommariva as Chief Legal Counsel. Federico reports to the CEO and is member of the management team. Federico Sommariva has many years of legal and management experience in the Lifesciences industry. Since June 2013, he has worked for Gilead Sciences based in Milan (Italy), with increasing responsibilities. Most recently, he acted as Director and Global Legal Business Partner Oncology. He also served for 1.5 years as interim Head of Legal and Compliance for Gilead Sciences Romania. Federico studied law at the University of Milan and started his professional career as Legal Counsel Secondee at H&M in Rome (Italy).
お知らせ • Feb 11Cosmo Pharmaceuticals N.V. Announces the Appointment of Andrea Cherubini as Chief AI OfficerCosmo Pharmaceuticals N.V. announced the appointment of Andrea Cherubini as Chief AI Officer effective immediately. This important decision reflects Cosmo's commitment to integrating Artificial Intelligence as a core strategic pillar in its future growth and innovation roadmap. Andrea will report to the CEO and will be member of the executive leadership team. Andrea has been pivotal in the development and commercialization of Cosmo's GI GeniusT. As Senior Vice President - Science, AI, and Data, he was leading the development of innovative AI solutions for the Cosmo Intelligent Medical Devices division since 2018. His extensive clinical expertise, data-driven approach, and leadership in AI have already transformed patient outcomes, showcasing the real-world impact of AI in medical applications. AI as a Strategic Growth Driver In his new role as Chief AI Officer, Andrea will spearhead the expansion of AI beyond endoscopy, embedding it across Cosmo's entire portfolio to accelerate innovation, enhance efficiencies, and unlock new value for both patients and shareholders. This includes, among others: Gastroenterology Pipeline - Advancing AI applications in drug development, particularly for Bile Acid Diarrhea (BAD), to drive precision medicine and predictive analytics in GI disorders. Dermatology Pipeline - Leveraging AI to optimize clinical trial design, patient selection, and personalized treatment pathways for Breezula and other dermatological innovations. AI-Enabled Drug Discovery & Development - Expanding AI's role in R&D, regulatory strategies, and digital health applications, reinforcing Cosmo's position as a leader in AI-driven healthcare solutions. At the same time, Andrea will continue to play a critical role in shaping Cosmo's Intelligent Medical Devices division's AI roadmap, reinforcing GI GeniusT as the leading real-time AI platform in endoscopy.
お知らせ • Jan 21+ 1 more updateCosmo Pharmaceuticals N.V. to Report Fiscal Year 2024 Results on Mar 06, 2025Cosmo Pharmaceuticals N.V. announced that they will report fiscal year 2024 results on Mar 06, 2025
お知らせ • Jan 08Cosmo Pharmaceuticals N.V. to Report Fiscal Year 2024 Final Results on Mar 20, 2025Cosmo Pharmaceuticals N.V. announced that they will report fiscal year 2024 final results at 12:00 PM, Central European Standard Time on Mar 20, 2025
お知らせ • Oct 12Cosmo Pharmaceuticals N.V. Announces Chief Financial Officer ChangesCosmo Pharmaceuticals N.V. announced the appointment of Svetlana Sigalova as its new Chief Financial Officer, effective November 11, 2024. Svetlana will succeed Niall Donnelly, who has served as CFO since 2016. Svetlana Sigalova brings a wealth of expertise from her time at Moderna, where she served as Vice President of Commercial Finance and led the financial operations for over $6 billion in global sales. Her proven ability to develop financial infrastructure and planning systems was pivotal in Moderna's rapid growth during the pandemic. Prior to Moderna, Svetlana held senior finance leadership positions at Alexion Pharmaceuticals and Vertex Pharmaceuticals, where she managed multibillion-dollar revenue streams, built high-performance finance teams, and drove operational efficiency. Niall will transition to a strategic new role as EVP - Corporate Governance & Chief Sustainability Officer, where he will report to CEO and play a key part in strengthening Cosmo's corporate governance framework and driving the Company's mission to advance environmental, social, and governance (ESG) initiatives. With a focus on achieving carbon footprint reduction and sustainable business practices, Niall's leadership will ensure Cosmo continues to build a strong and responsible organization with a robust governance structure that aligns with the Company's long-term growth and value creation. He will also remain an executive member of the Board of Directors of Cosmo.
お知らせ • Apr 28Cosmo Pharmaceuticals N.V. Announces Executive Changes at the Upcoming Annual General Meeting on 24 May 2024Cosmo Pharmaceuticals N.V. announced the appointment of Giovanni Di Napoli as its new Chief Executive Officer, along with changes to its Board of Directors, at the upcoming Annual General Meeting (AGM) on 24 May 2024. At the same time, it will be proposed at the AGM to appoint longstanding Cosmo CEO Alessandro Della Cha as the new Chairman of Cosmo. Alessandro joined Cosmo in 2006 as member of the Board of Directors and was appointed as CEO of the Company in 2014. Giovanni is an accomplished leader with an excellent track record and joins Cosmo from Medtronic where he held various leadership positions since 2008. Until recently, Giovanni was President of Medtronic's Endoscopy Operating Unit located in Santa Clara, California. In this position, he and his team were responsible for one of the most innovative and fast-growing portfolios in the endoscopy market, which included technologies such as Endoflip, Pillcam, and GI Genius. From July 2017 to November 2020, he was Vice President and General Manager GIH - Gastrointestinal and Hepatology and was Vice President Sales U.S. - GI Solutions from February 2015 to July 2017. From April 2012 to February 2015, he was Director of Sales Marketing for Western Europe. Previously, Giovanni held various leadership positions at Johnson Johnson Medical (2001- 2010). Giovanni has an MBA from the Universita Bocconi, Milan, Italy.
New Risk • Mar 24New major risk - Dividend sustainabilityThe dividend is not well covered by earnings and cash flows. Dividend per share is over 28x earnings per share. Cash payout ratio: 175% Dividend yield: 2.9% This is considered a major risk. Companies that pay out too much of their earnings and cash flows are at risk of having to reduce or cut their dividend in future. If earnings or cash flows stagnate or fall, then there may not be enough to maintain the same dividend. Or in extreme cases, companies may opt to dig into capital reserves or take on debt to maintain the dividend. For dividend paying companies, any reduction in the dividend can significantly impact the share price. Currently, the following risks have been identified for the company: Major Risk Dividend is not well covered by earnings and cash flows. Dividend per share is over 28x earnings per share. Cash payout ratio: 175% Minor Risks Large one-off items impacting financial results. Profit margins are more than 30% lower than last year (1.2% net profit margin).
Reported Earnings • Mar 22Full year 2023 earnings released: EPS: €0.071 (vs €1.05 in FY 2022)Full year 2023 results: EPS: €0.071 (down from €1.05 in FY 2022). Revenue: €96.7m (down 5.3% from FY 2022). Net income: €1.15m (down 93% from FY 2022). Profit margin: 1.2% (down from 17% in FY 2022). The decrease in margin was primarily driven by higher expenses. Revenue is forecast to grow 26% p.a. on average during the next 3 years, compared to a 5.8% growth forecast for the Pharmaceuticals industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 37% per year but the company’s share price has fallen by 8% per year, which means it is significantly lagging earnings.
お知らせ • Mar 22Cosmo Pharmaceuticals N.V. to Report Fiscal Year 2023 Final Results on Apr 30, 2024Cosmo Pharmaceuticals N.V. announced that they will report fiscal year 2023 final results on Apr 30, 2024
お知らせ • Feb 15Cosmo Pharmaceuticals N.V. to Report First Half, 2024 Results on Jul 25, 2024Cosmo Pharmaceuticals N.V. announced that they will report first half, 2024 results on Jul 25, 2024
お知らせ • Dec 06+ 1 more updateCosmo Pharmaceuticals N.V., Annual General Meeting, May 24, 2024Cosmo Pharmaceuticals N.V., Annual General Meeting, May 24, 2024.
Reported Earnings • Jul 28First half 2023 earnings released: EPS: €0.092 (vs €0.48 in 1H 2022)First half 2023 results: EPS: €0.092 (down from €0.48 in 1H 2022). Revenue: €43.7m (up 5.2% from 1H 2022). Net income: €1.49m (down 81% from 1H 2022). Profit margin: 3.4% (down from 19% in 1H 2022). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 28% p.a. on average during the next 3 years, compared to a 6.5% growth forecast for the Pharmaceuticals industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 78% per year but the company’s share price has fallen by 21% per year, which means it is significantly lagging earnings.
Upcoming Dividend • May 24Upcoming dividend of €1.05 per share at 2.0% yieldEligible shareholders must have bought the stock before 31 May 2023. Payment date: 02 June 2023. The company is paying out more than 100% of its profits but is generating plenty of cash to support the dividend. Trailing yield: 2.0%. Lower than top quartile of British dividend payers (5.8%). Lower than average of industry peers (2.4%).
Reported Earnings • Mar 25Full year 2022 earnings released: EPS: €1.05 (vs €1.29 in FY 2021)Full year 2022 results: EPS: €1.05 (down from €1.29 in FY 2021). Revenue: €102.1m (up 57% from FY 2021). Net income: €17.2m (down 21% from FY 2021). Profit margin: 17% (down from 33% in FY 2021). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 24% p.a. on average during the next 3 years, compared to a 6.5% growth forecast for the Pharmaceuticals industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 106% per year but the company’s share price has fallen by 4% per year, which means it is significantly lagging earnings.
お知らせ • Dec 20+ 2 more updatesCosmo Pharmaceuticals N.V., Annual General Meeting, May 26, 2023Cosmo Pharmaceuticals N.V., Annual General Meeting, May 26, 2023.
Board Change • Nov 16No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 8 experienced directors. 4 highly experienced directors. No independent directors (7 non-independent directors). Non-Executive Director Kevin Donovan was the last director to join the board, commencing their role in 2016. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.
Reported Earnings • Jul 29First half 2022 earnings releasedFirst half 2022 results: Revenue: (down 100% from 1H 2021). Net income: (up €5.74m from 1H 2021). Profit margin: (up from net loss in 1H 2021). The move to profitability was driven by lower expenses. Over the next year, revenue is forecast to grow 50% while the industry in the United Kingdom is not expected to grow. Over the last 3 years on average, earnings per share has increased by 110% per year but the company’s share price has fallen by 15% per year, which means it is significantly lagging earnings.
Valuation Update With 7 Day Price Move • Jun 17Investor sentiment deteriorated over the past weekAfter last week's 15% share price decline to CHF42.90, the stock trades at a forward P/E ratio of 41x. Average forward P/E is 19x in the Pharmaceuticals industry in the United Kingdom. Total loss to shareholders of 52% over the past three years.
Board Change • Apr 27No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 8 experienced directors. 4 highly experienced directors. No independent directors (7 non-independent directors). Non-Executive Director Kevin Donovan was the last director to join the board, commencing their role in 2016. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.
Breakeven Date Change • Dec 31Forecast breakeven date pushed back to 2022The 2 analysts covering Cosmo Pharmaceuticals previously expected the company to break even in 2021. New consensus forecast suggests the company will make a profit of €3.95m in 2022. Average annual earnings growth of 37% is required to achieve expected profit on schedule.
Executive Departure • Nov 29Non-Executive Director Eimear Cowhey has left the companyOn the 16th of November, Eimear Cowhey's tenure as Non-Executive Director ended after 4.5 years in the role. We don't have any record of a personal shareholding under Eimear's name. A total of 3 executives have left over the last 12 months. The current median tenure of the management team is 5.25 years.
Executive Departure • Nov 29Non-Executive Director Eimear Cowhey has left the companyOn the 16th of November, Eimear Cowhey's tenure as Non-Executive Director ended after 4.5 years in the role. We don't have any record of a personal shareholding under Eimear's name. A total of 3 executives have left over the last 12 months. The current median tenure of the management team is 5.25 years.
Executive Departure • Nov 29Non-Executive Director Eimear Cowhey has left the companyOn the 16th of November, Eimear Cowhey's tenure as Non-Executive Director ended after 4.5 years in the role. We don't have any record of a personal shareholding under Eimear's name. A total of 3 executives have left over the last 12 months. The current median tenure of the management team is 5.25 years.
Executive Departure • Nov 29Non-Executive Director Eimear Cowhey has left the companyOn the 16th of November, Eimear Cowhey's tenure as Non-Executive Director ended after 4.5 years in the role. We don't have any record of a personal shareholding under Eimear's name. A total of 3 executives have left over the last 12 months. The current median tenure of the management team is 5.25 years.
Executive Departure • Nov 29Non-Executive Director Eimear Cowhey has left the companyOn the 16th of November, Eimear Cowhey's tenure as Non-Executive Director ended after 4.5 years in the role. We don't have any record of a personal shareholding under Eimear's name. A total of 3 executives have left over the last 12 months. The current median tenure of the management team is 5.25 years.
Executive Departure • Nov 29Non-Executive Director Eimear Cowhey has left the companyOn the 16th of November, Eimear Cowhey's tenure as Non-Executive Director ended after 4.5 years in the role. We don't have any record of a personal shareholding under Eimear's name. A total of 3 executives have left over the last 12 months. The current median tenure of the management team is 5.25 years.
Executive Departure • Nov 29Non-Executive Director Eimear Cowhey has left the companyOn the 16th of November, Eimear Cowhey's tenure as Non-Executive Director ended after 4.5 years in the role. We don't have any record of a personal shareholding under Eimear's name. A total of 3 executives have left over the last 12 months. The current median tenure of the management team is 5.25 years.
Executive Departure • Nov 28Non-Executive Director Eimear Cowhey has left the companyOn the 16th of November, Eimear Cowhey's tenure as Non-Executive Director ended after 4.5 years in the role. We don't have any record of a personal shareholding under Eimear's name. A total of 3 executives have left over the last 12 months. The current median tenure of the management team is 5.25 years.
Executive Departure • Nov 28Non-Executive Director Eimear Cowhey has left the companyOn the 16th of November, Eimear Cowhey's tenure as Non-Executive Director ended after 4.5 years in the role. We don't have any record of a personal shareholding under Eimear's name. A total of 3 executives have left over the last 12 months. The current median tenure of the management team is 5.25 years.
Executive Departure • Nov 28Non-Executive Director Eimear Cowhey has left the companyOn the 16th of November, Eimear Cowhey's tenure as Non-Executive Director ended after 4.5 years in the role. We don't have any record of a personal shareholding under Eimear's name. A total of 3 executives have left over the last 12 months. The current median tenure of the management team is 5.25 years.
Executive Departure • Nov 28Non-Executive Director Eimear Cowhey has left the companyOn the 16th of November, Eimear Cowhey's tenure as Non-Executive Director ended after 4.5 years in the role. We don't have any record of a personal shareholding under Eimear's name. A total of 3 executives have left over the last 12 months. The current median tenure of the management team is 5.25 years.
Executive Departure • Nov 28Non-Executive Director Eimear Cowhey has left the companyOn the 16th of November, Eimear Cowhey's tenure as Non-Executive Director ended after 4.5 years in the role. We don't have any record of a personal shareholding under Eimear's name. A total of 3 executives have left over the last 12 months. The current median tenure of the management team is 5.25 years.
Executive Departure • Nov 28Non-Executive Director Eimear Cowhey has left the companyOn the 16th of November, Eimear Cowhey's tenure as Non-Executive Director ended after 4.5 years in the role. We don't have any record of a personal shareholding under Eimear's name. A total of 3 executives have left over the last 12 months. The current median tenure of the management team is 5.25 years.
Executive Departure • Nov 28Non-Executive Director Eimear Cowhey has left the companyOn the 16th of November, Eimear Cowhey's tenure as Non-Executive Director ended after 4.5 years in the role. We don't have any record of a personal shareholding under Eimear's name. A total of 3 executives have left over the last 12 months. The current median tenure of the management team is 5.25 years.
Executive Departure • Nov 28Non-Executive Director Eimear Cowhey has left the companyOn the 16th of November, Eimear Cowhey's tenure as Non-Executive Director ended after 4.5 years in the role. We don't have any record of a personal shareholding under Eimear's name. A total of 3 executives have left over the last 12 months. The current median tenure of the management team is 5.25 years.
Executive Departure • Nov 27Non-Executive Director Eimear Cowhey has left the companyOn the 16th of November, Eimear Cowhey's tenure as Non-Executive Director ended after 4.5 years in the role. We don't have any record of a personal shareholding under Eimear's name. A total of 3 executives have left over the last 12 months. The current median tenure of the management team is 5.25 years.
Executive Departure • Nov 27Non-Executive Director Eimear Cowhey has left the companyOn the 16th of November, Eimear Cowhey's tenure as Non-Executive Director ended after 4.5 years in the role. We don't have any record of a personal shareholding under Eimear's name. A total of 3 executives have left over the last 12 months. The current median tenure of the management team is 5.25 years.
Executive Departure • Nov 27Non-Executive Director Eimear Cowhey has left the companyOn the 16th of November, Eimear Cowhey's tenure as Non-Executive Director ended after 4.5 years in the role. We don't have any record of a personal shareholding under Eimear's name. A total of 3 executives have left over the last 12 months. The current median tenure of the management team is 5.25 years.
Executive Departure • Nov 27Non-Executive Director Eimear Cowhey has left the companyOn the 16th of November, Eimear Cowhey's tenure as Non-Executive Director ended after 4.5 years in the role. We don't have any record of a personal shareholding under Eimear's name. A total of 3 executives have left over the last 12 months. The current median tenure of the management team is 5.25 years.
Executive Departure • Nov 27Non-Executive Director Eimear Cowhey has left the companyOn the 16th of November, Eimear Cowhey's tenure as Non-Executive Director ended after 4.5 years in the role. We don't have any record of a personal shareholding under Eimear's name. A total of 3 executives have left over the last 12 months. The current median tenure of the management team is 5.25 years.
Executive Departure • Nov 27Non-Executive Director Eimear Cowhey has left the companyOn the 16th of November, Eimear Cowhey's tenure as Non-Executive Director ended after 4.5 years in the role. We don't have any record of a personal shareholding under Eimear's name. A total of 3 executives have left over the last 12 months. The current median tenure of the management team is 5.25 years.
Executive Departure • Nov 27Non-Executive Director Eimear Cowhey has left the companyOn the 16th of November, Eimear Cowhey's tenure as Non-Executive Director ended after 4.5 years in the role. We don't have any record of a personal shareholding under Eimear's name. A total of 3 executives have left over the last 12 months. The current median tenure of the management team is 5.25 years.
Executive Departure • Nov 27Non-Executive Director Eimear Cowhey has left the companyOn the 16th of November, Eimear Cowhey's tenure as Non-Executive Director ended after 4.5 years in the role. We don't have any record of a personal shareholding under Eimear's name. A total of 3 executives have left over the last 12 months. The current median tenure of the management team is 5.25 years.
Executive Departure • Nov 27Non-Executive Director Eimear Cowhey has left the companyOn the 16th of November, Eimear Cowhey's tenure as Non-Executive Director ended after 4.5 years in the role. We don't have any record of a personal shareholding under Eimear's name. A total of 3 executives have left over the last 12 months. The current median tenure of the management team is 5.25 years.
Executive Departure • Nov 27Non-Executive Director Eimear Cowhey has left the companyOn the 16th of November, Eimear Cowhey's tenure as Non-Executive Director ended after 4.5 years in the role. We don't have any record of a personal shareholding under Eimear's name. A total of 3 executives have left over the last 12 months. The current median tenure of the management team is 5.25 years.
Executive Departure • Nov 27Non-Executive Director Eimear Cowhey has left the companyOn the 16th of November, Eimear Cowhey's tenure as Non-Executive Director ended after 4.5 years in the role. We don't have any record of a personal shareholding under Eimear's name. A total of 3 executives have left over the last 12 months. The current median tenure of the management team is 5.25 years.
Executive Departure • Nov 27Non-Executive Director Eimear Cowhey has left the companyOn the 16th of November, Eimear Cowhey's tenure as Non-Executive Director ended after 4.5 years in the role. We don't have any record of a personal shareholding under Eimear's name. A total of 3 executives have left over the last 12 months. The current median tenure of the management team is 5.25 years.
Executive Departure • Nov 27Non-Executive Director Eimear Cowhey has left the companyOn the 16th of November, Eimear Cowhey's tenure as Non-Executive Director ended after 4.5 years in the role. We don't have any record of a personal shareholding under Eimear's name. A total of 3 executives have left over the last 12 months. The current median tenure of the management team is 5.25 years.
Executive Departure • Nov 27Non-Executive Director Eimear Cowhey has left the companyOn the 16th of November, Eimear Cowhey's tenure as Non-Executive Director ended after 4.5 years in the role. We don't have any record of a personal shareholding under Eimear's name. A total of 3 executives have left over the last 12 months. The current median tenure of the management team is 5.25 years.
Executive Departure • Nov 27Non-Executive Director Eimear Cowhey has left the companyOn the 16th of November, Eimear Cowhey's tenure as Non-Executive Director ended after 4.5 years in the role. We don't have any record of a personal shareholding under Eimear's name. A total of 3 executives have left over the last 12 months. The current median tenure of the management team is 5.25 years.
Executive Departure • Nov 27Non-Executive Director Eimear Cowhey has left the companyOn the 16th of November, Eimear Cowhey's tenure as Non-Executive Director ended after 4.5 years in the role. We don't have any record of a personal shareholding under Eimear's name. A total of 3 executives have left over the last 12 months. The current median tenure of the management team is 5.25 years.
Executive Departure • Nov 26Non-Executive Director Eimear Cowhey has left the companyOn the 16th of November, Eimear Cowhey's tenure as Non-Executive Director ended after 4.5 years in the role. We don't have any record of a personal shareholding under Eimear's name. A total of 3 executives have left over the last 12 months. The current median tenure of the management team is 5.25 years.
Executive Departure • Nov 26Non-Executive Director Eimear Cowhey has left the companyOn the 16th of November, Eimear Cowhey's tenure as Non-Executive Director ended after 4.5 years in the role. We don't have any record of a personal shareholding under Eimear's name. A total of 3 executives have left over the last 12 months. The current median tenure of the management team is 5.25 years.
Executive Departure • Nov 26Non-Executive Director Eimear Cowhey has left the companyOn the 16th of November, Eimear Cowhey's tenure as Non-Executive Director ended after 4.5 years in the role. We don't have any record of a personal shareholding under Eimear's name. A total of 3 executives have left over the last 12 months. The current median tenure of the management team is 5.25 years.
Executive Departure • Nov 26Non-Executive Director Eimear Cowhey has left the companyOn the 16th of November, Eimear Cowhey's tenure as Non-Executive Director ended after 4.5 years in the role. We don't have any record of a personal shareholding under Eimear's name. A total of 3 executives have left over the last 12 months. The current median tenure of the management team is 5.25 years.
Executive Departure • Nov 26Non-Executive Director Eimear Cowhey has left the companyOn the 16th of November, Eimear Cowhey's tenure as Non-Executive Director ended after 4.5 years in the role. We don't have any record of a personal shareholding under Eimear's name. A total of 3 executives have left over the last 12 months. The current median tenure of the management team is 5.25 years.
Executive Departure • Nov 26Non-Executive Director Eimear Cowhey has left the companyOn the 16th of November, Eimear Cowhey's tenure as Non-Executive Director ended after 4.5 years in the role. We don't have any record of a personal shareholding under Eimear's name. A total of 3 executives have left over the last 12 months. The current median tenure of the management team is 5.25 years.
Executive Departure • Nov 26Non-Executive Director Eimear Cowhey has left the companyOn the 16th of November, Eimear Cowhey's tenure as Non-Executive Director ended after 4.5 years in the role. We don't have any record of a personal shareholding under Eimear's name. A total of 3 executives have left over the last 12 months. The current median tenure of the management team is 5.25 years.
Executive Departure • Nov 26Non-Executive Director Eimear Cowhey has left the companyOn the 16th of November, Eimear Cowhey's tenure as Non-Executive Director ended after 4.5 years in the role. We don't have any record of a personal shareholding under Eimear's name. A total of 3 executives have left over the last 12 months. The current median tenure of the management team is 5.25 years.
Executive Departure • Nov 26Non-Executive Director Eimear Cowhey has left the companyOn the 16th of November, Eimear Cowhey's tenure as Non-Executive Director ended after 4.5 years in the role. We don't have any record of a personal shareholding under Eimear's name. A total of 3 executives have left over the last 12 months. The current median tenure of the management team is 5.25 years.
Executive Departure • Nov 26Non-Executive Director Eimear Cowhey has left the companyOn the 16th of November, Eimear Cowhey's tenure as Non-Executive Director ended after 4.5 years in the role. We don't have any record of a personal shareholding under Eimear's name. A total of 3 executives have left over the last 12 months. The current median tenure of the management team is 5.25 years.
Executive Departure • Nov 26Non-Executive Director Eimear Cowhey has left the companyOn the 16th of November, Eimear Cowhey's tenure as Non-Executive Director ended after 4.5 years in the role. We don't have any record of a personal shareholding under Eimear's name. A total of 3 executives have left over the last 12 months. The current median tenure of the management team is 5.25 years.
Executive Departure • Nov 26Non-Executive Director Eimear Cowhey has left the companyOn the 16th of November, Eimear Cowhey's tenure as Non-Executive Director ended after 4.5 years in the role. We don't have any record of a personal shareholding under Eimear's name. A total of 3 executives have left over the last 12 months. The current median tenure of the management team is 5.25 years.
Executive Departure • Nov 25Non-Executive Director Eimear Cowhey has left the companyOn the 16th of November, Eimear Cowhey's tenure as Non-Executive Director ended after 4.5 years in the role. We don't have any record of a personal shareholding under Eimear's name. A total of 3 executives have left over the last 12 months. The current median tenure of the management team is 5.25 years.
Executive Departure • Nov 25Non-Executive Director Eimear Cowhey has left the companyOn the 16th of November, Eimear Cowhey's tenure as Non-Executive Director ended after 4.5 years in the role. We don't have any record of a personal shareholding under Eimear's name. A total of 3 executives have left over the last 12 months. The current median tenure of the management team is 5.25 years.
Executive Departure • Nov 25Non-Executive Director Eimear Cowhey has left the companyOn the 16th of November, Eimear Cowhey's tenure as Non-Executive Director ended after 4.5 years in the role. We don't have any record of a personal shareholding under Eimear's name. A total of 3 executives have left over the last 12 months. The current median tenure of the management team is 5.25 years.
Executive Departure • Nov 25Non-Executive Director Eimear Cowhey has left the companyOn the 16th of November, Eimear Cowhey's tenure as Non-Executive Director ended after 4.5 years in the role. We don't have any record of a personal shareholding under Eimear's name. A total of 3 executives have left over the last 12 months. The current median tenure of the management team is 5.25 years.
Executive Departure • Nov 25Non-Executive Director Eimear Cowhey has left the companyOn the 16th of November, Eimear Cowhey's tenure as Non-Executive Director ended after 4.5 years in the role. We don't have any record of a personal shareholding under Eimear's name. A total of 3 executives have left over the last 12 months. The current median tenure of the management team is 5.25 years.
Executive Departure • Nov 25Non-Executive Director Eimear Cowhey has left the companyOn the 16th of November, Eimear Cowhey's tenure as Non-Executive Director ended after 4.5 years in the role. We don't have any record of a personal shareholding under Eimear's name. A total of 3 executives have left over the last 12 months. The current median tenure of the management team is 5.25 years.
Executive Departure • Nov 25Non-Executive Director Eimear Cowhey has left the companyOn the 16th of November, Eimear Cowhey's tenure as Non-Executive Director ended after 4.5 years in the role. We don't have any record of a personal shareholding under Eimear's name. A total of 3 executives have left over the last 12 months. The current median tenure of the management team is 5.25 years.
Executive Departure • Nov 25Non-Executive Director Eimear Cowhey has left the companyOn the 16th of November, Eimear Cowhey's tenure as Non-Executive Director ended after 4.5 years in the role. We don't have any record of a personal shareholding under Eimear's name. A total of 3 executives have left over the last 12 months. The current median tenure of the management team is 5.25 years.
Breakeven Date Change • Sep 23Forecast to breakeven in 2021The 3 analysts covering Cosmo Pharmaceuticals expect the company to break even for the first time. New consensus forecast suggests the company will make a profit of €5.22m in 2021. Earnings growth of 59% is required to achieve expected profit on schedule.
Breakeven Date Change • Aug 04Forecast breakeven moved forward to 2021The 3 analysts covering Cosmo Pharmaceuticals previously expected the company to break even in 2022. New consensus forecast suggests the company will make a profit of €6.00m in 2021. Earnings growth of 60% is required to achieve expected profit on schedule.
Reported Earnings • Aug 02First half 2021 earnings released: €0.40 loss per share (vs €0.21 loss in 1H 2020)The company reported a soft first half result with increased losses and weaker control over costs, although revenues improved. First half 2021 results: Revenue: €28.4m (up 9.8% from 1H 2020). Net loss: €5.74m (loss widened 90% from 1H 2020). Over the last 3 years on average, earnings per share has increased by 34% per year but the company’s share price has fallen by 14% per year, which means it is significantly lagging earnings.
Executive Departure • Jun 04Non-Executive Director Hans Tanner has left the companyOn the 29th of May, Hans Tanner's tenure as Non-Executive Director ended. We don't have any record of a personal shareholding under Hans' name. A total of 3 executives have left over the last 12 months. The current median tenure of the management team is 4.83 years.
Reported Earnings • Mar 27Full year 2020 earnings released: €0.55 loss per share (vs €1.67 loss in FY 2019)The company reported a decent full year result with reduced losses and improved control over expenses, although revenues were weaker. Full year 2020 results: Revenue: €60.9m (down 2.5% from FY 2019). Net loss: €7.90m (loss narrowed 68% from FY 2019). Over the last 3 years on average, earnings per share has increased by 33% per year but the company’s share price has fallen by 13% per year, which means it is significantly lagging earnings.
Is New 90 Day High Low • Feb 06New 90-day high: CHF87.80The company is up 10.0% from its price of CHF79.90 on 06 November 2020. The British market is up 12% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Pharmaceuticals industry, which is down 11% over the same period.
お知らせ • Dec 04Cosmo Pharmaceuticals Announces Licence of Lumeblue (Methylene Blue MMX) China Rights to China Medical System Holdings LtdCosmo Pharmaceuticals N.V. announced that it has licensed the Chinese rights for Lumeblue™ to China Medical System Holdings Ltd. Lumeblue™ is Cosmo's recently EMA approved drug for the detection of lesions during colonoscopy. CMS is a well-established, innovation-driven specialty pharma with a focus on sales and marketing in China. CMS concentrates on innovative products that are global first-in-class or with the best efficacy or best cost-effectiveness in the same class due to their innovative formulations or drug delivery systems, and has built up an innovative pipeline with great market potential and competitive differentiation advantages at relatively high innovation level, covering various therapeutic fields. Meanwhile, CMS has proven and successful experience in drug promotion for over two decades, and established a professional, compliant and efficient academic promotion system. CMS is listed on the Main Board of the Stock Exchange of Hong Kong. CMS will pay Cosmo a USD 5m upon the earlier of (a) the execution of a supply agreement or (b) the forty-fifth (45th) day from the execution of this agreement, plus royalties and potential regulatory and commercial milestones. Cosmo will be the exclusive supplier of Lumeblue™.
お知らせ • Dec 01Cosmo Pharmaceuticals Appoints H. Jurgen Lenz as New Chief Medical OfficerCosmo Pharmaceuticals N.V. announced that Dr. H. Jurgen Lenz, MD, has been appointed Chief Medical Officer starting from December 1st, 2020. Dr. Lenz is a gastroenterologist and is Chief of the Division of Gastroenterology at Scripps Memorial Hospital, La Jolla, CA, USA. He is member of the American Gastroenterological Association (AGA), American College of Gastroenterology (ACG), American Society for Gastrointestinal Endoscopy (ASGE) and American Association for the Study of Liver Diseases (AASLD).
お知らせ • Nov 24Cosmo Pharmaceuticals N.V. Announces Senior Leadership Changes, Effective January 1, 2021Cosmo Pharmaceuticals N.V. announced two senior leadership changes which will take effect from the 1st of January 2021. Mr. Giuseppe Cipriano, the current COO, will be appointed to the position of Chief People Officer of Cosmo and will take the lead for all aspects related to managing human resources and industrial relations. Mr. Cipriano has been COO since 2001. Mr. Marco Lecchi, the current Head of Internal Audit, will be appointed to the position of Chief Operating Officer. Mr. Lecchi has been with Cosmo since 2001 and served as Deputy CFO since 2007 prior to his appointment as Head of Internal Audit in 2016.
お知らせ • Nov 19Cosmo Pharmaceuticals Announces Expansion of Agreement with Dr. Falk Pharma for Rifamycin SV MMXCosmo Pharmaceuticals N.V. announced that it has expanded its existing license agreement with Dr. Falk Pharma Gmbh ("Dr. Falk") to include Rifamycin SV MMX in the new 600mg formulation currently tested in the IBS-D indication. Under the agreement with Dr Falk, Cosmo will receive a further &euro2m down-payment plus reimbursement of a portion of the expenses borne for the development of the 600mg formulation plus a supply price which incorporates a high double-digit percentage of sales. Dr. Falk will also bear a portion of the future costs for the ongoing developments. Rifamycin SV MMX 200mg is already approved in the US and EU for the treatment of travelers' diarrhea and it is licensed to Dr. Falk for the EU and other countries and is marketed under the brand name Relafalk®, whereas it is licensed to RedHill BioPharma Ltd. for the US where it is marketed under the brand name Aemcolo®. A Phase II clinical study with Rifamycin 600mg in IBS-D indication is currently ongoing and results are expected by year end.